AtriCure Publishes Q3 2026 Earnings Call Transcript

By Public Technologies
  • AtriCure's November 4 third-quarter 2026 earnings call featured CEO Michael Carrel, CFO Angie Wirick and equity analysts.
  • Quarterly revenue rose 15% to $154.5 million, driven by pain management, open ablation and appendage management.
  • Management raised full-year adjusted EBITDA guidance to $91 million-$94 million; revenue is now expected at $606 million-$610 million.
  • The outlook remains cautious amid U.S. hybrid ablation weakness and international headwinds, with no significant overseas recovery expected this year.
  • BoxX-NoAF enrollment remains on track for year-end completion, with initial data expected in spring 2027; FDA approval is anticipated around mid-2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AtriCure Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.